Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 3/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9607586 | 0.89 | NOS3 (0.40) | PDE10AATRCYP1A2 | |
| SCHEMBL8777349 | 0.87 | CYP1A2 (0.45) | PDE10APIK3CAPIK3CDPIK3CGCYP1A2 | |
| SCHEMBL8777057 | 0.86 | CYP1A2 (0.38) | PDE10APIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8776852 | 0.85 | CYP1A2 (0.42) | PDE10APIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL8776966 | 0.84 | PDE10A (0.46) | PDE10AATRCYP1A2ABCG2 | |
| SCHEMBL8777303 | 0.84 | PDE10A (0.46) | PDE10ACYP1A2 | |
| SCHEMBL18707658 | 0.84 | CYP1A2 (0.42) | PDE10ACYP1A2 | |
| SCHEMBL8775836 | 0.83 | FYN (0.43) | PDE10APTGER4PIK3CAPIK3CDMTOR | |
| SCHEMBL8776938 | 0.83 | PDE10A (0.51) | PDE10ACYP1A2 | |
| SCHEMBL8776955 | 0.82 | CYP1A2 (0.42) | PDE10ACYP1A2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | PDE10A 1335/4885PTGER4 4435/4885PIK3CA 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.